Search

Search Constraints

You searched for: Author/Creator Kumar, Shaji

Search Results

2. A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma. (25th September 2015)

3. Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. Issue 12 (2nd December 2015)

4. Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. Issue 11 (2nd October 2018)

5. A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR‐CD) for untreated low‐grade non‐Hodgkin lymphoma requiring therapy. Issue 5 (22nd March 2017)

7. Implications and outcomes of MRD‐negative multiple myeloma patients with immunofixation positivity. Issue 3 (30th December 2019)

8. Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia. Issue 3 (31st December 2019)

9. Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. (29th August 2019)

10. Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. Issue 1 (December 2018)